Literature DB >> 15675722

Dementia in idiopathic Parkinson's syndrome.

Gerd A Fuchs1, Irene Gemende, Birgit Herting, Mathias R Lemke, Christian Oehlwein, Heinz Reichmann, Jürgen Rieke, David Emmans, Jens Volkmann.   

Abstract

Approximately 25% of patients with idiopathic Parkinson's disease (IPD) later develop dementia, with the typical characteristics as detailed in ICD-10 and DSM-IV. Differential diagnosis has to exclude dementia due to Lewy bodies, subcortical vascular encephalopathy and subcortical dementia due to progressive supranuclear paralysis or corticobasal degeneration. Several studies showed promising results for cholinesterase inhibitors such as donepezile, rivastigmine and galantamine. The demented Parkinsonian patients then present with improvement in cognitive function while motor skills do not deteriorate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15675722     DOI: 10.1007/s00415-004-1607-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  Parkinson's disease and dementia with Lewy bodies: one disease or two?

Authors:  Irene Hegeman Richard; Michelle Papka; Ana Rubio; Roger Kurlan
Journal:  Mov Disord       Date:  2002-11       Impact factor: 10.338

Review 2.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

3.  Cholinesterase inhibition in Parkinson's disease.

Authors:  M Hutchinson; E Fazzini
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

Review 4.  Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies.

Authors:  I G McKeith; E K Perry; R H Perry
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

5.  Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study.

Authors:  W Samuel; M Caligiuri; D Galasko; J Lacro; M Marini; F S McClure; K Warren; D V Jeste
Journal:  Int J Geriatr Psychiatry       Date:  2000-09       Impact factor: 3.485

6.  Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

Authors:  I McKeith; T Del Ser; P Spano; M Emre; K Wesnes; R Anand; A Cicin-Sain; R Ferrara; R Spiegel
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

7.  Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.

Authors:  D Aarsland; K Laake; J P Larsen; C Janvin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

8.  Frequency of dementia in Parkinson disease.

Authors:  D Aarsland; E Tandberg; J P Larsen; J L Cummings
Journal:  Arch Neurol       Date:  1996-06

9.  Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.

Authors:  D Aarsland; M Hutchinson; J P Larsen
Journal:  Int J Geriatr Psychiatry       Date:  2003-10       Impact factor: 3.485

10.  Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.

Authors:  N Giladi; H Shabtai; T Gurevich; B Benbunan; M Anca; A D Korczyn
Journal:  Acta Neurol Scand       Date:  2003-11       Impact factor: 3.209

View more
  5 in total

Review 1.  Behavioral phenotyping of mouse models of Parkinson's disease.

Authors:  Tonya N Taylor; James G Greene; Gary W Miller
Journal:  Behav Brain Res       Date:  2010-03-06       Impact factor: 3.332

2.  Cognitive impairment in Parkinson's disease.

Authors:  D Verbaan; J Marinus; M Visser; S M van Rooden; A M Stiggelbout; H A M Middelkoop; J J van Hilten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-18       Impact factor: 10.154

3.  Frequency of cognitive impairment and depression in Parkinson's disease: A preliminary case-control study.

Authors:  Oluwadamilola O Ojo; Njideka U Okubadejo; Frank I Ojini; Mustapha A Danesi
Journal:  Niger Med J       Date:  2012-04

4.  Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice.

Authors:  Lilia Zurkovsky; Evgeny Bychkov; Elviche L Tsakem; Carley Siedlecki; Randy D Blakely; Eugenia V Gurevich
Journal:  Dis Model Mech       Date:  2012-08-03       Impact factor: 5.758

5.  Rivastigmine for the treatment of dementia associated with Parkinson's disease.

Authors:  Jennifer L Reingold; John C Morgan; Kapil D Sethi
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.